New follicular lymphoma treated with radiation plus antibody
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether adding a targeted antibody to standard radiation can help people with early-stage, newly diagnosed follicular lymphoma. It aims to control the lymphoma more effectively while keeping treatment safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older, and you have follicular lymphoma that tests positive for CD20 (a marker on the lymphoma cells).
- Your lymphoma has not been treated yet with radiation, chemotherapy, or immunotherapy.
- Your cancer stage is early (stage I or II) based on PET scan imaging.
- Your lymphoma is limited in size, with the largest lymph node/area measuring 7 cm or less.
- You can do usual activities fairly well (ECOG 0–2) and have blood counts that are high enough (ANC, platelets, and hemoglobin meet set minimums).
- If you can become pregnant (or someone could become pregnant from you), you must use effective birth control during treatment and for 18 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding obinutuzumab (an antibody medicine) to local radiation works better than radiation alone in early-stage follicular lymphoma. It aims to improve disease control while keeping treatment safe.
This trial tests a combination of radiation, an immunotherapy drug (tislelizumab), and chemotherapy (RCHOP) for people with previously untreated bulky follicular lymphoma. It aims to see if giving radiation first followed by the drug combo can improve outcomes for larger tumors.
This trial tests two antibody medications, tafasitamab and rituximab, as the first treatment for newly diagnosed follicular lymphoma. The goal is to see if this combination can effectively control the lymphoma and potentially reduce the need for more intensive therapies.
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
This trial combines a targeted antibody treatment called glofitamab with radiation therapy for people whose diffuse large B-cell lymphoma has come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This study tests a new drug combination (using two targeted medicines and an immunotherapy drug) versus a standard chemotherapy combination for people with untreated follicular lymphoma. The goal is to see if the new combo works better with fewer side effects.
Hear when a new Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.